This document is a Form 16 certificate issued by DelveInsight Business Research LLP to Yashveer Bhardwaj for the assessment year 2022-23. It summarizes the salary paid, taxes deducted, and other income. The key details are:
- Gross salary paid was Rs. 3,71,540
- Standard deduction of Rs. 50,000 was claimed
- Total income chargeable was Rs. 3,21,540
- Total deductions under Chapter VI-A were Rs. 19,812
- Net tax payable was Rs. 0
The document is a Form 16 certificate issued by Delveinsight Business Research LLP to Yashveer Bhardwaj for the assessment year 2022-23. It summarizes that a total amount of Rs. 371540 was paid to Yashveer Bhardwaj from April 2021 to March 2022, but no tax was deducted at source by Delveinsight Business Research LLP. The certificate is signed by Vishal Agrawal on behalf of Delveinsight Business Research LLP.
Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%?
For More Information- https://www.delveinsight.com/asco-conference/article/roche-glofitamab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Genmab/Abbvie presented spectacular findings from arm 2 of the EPCORE NHL-2 (Phase Ib/II) trial in the patients with R/R Follicular Lymphoma.
Read More- https://www.delveinsight.com/asco-conference/article/genmab-abbvies-epcoritamab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Teclistamab is a bispecific antibody that targets BCMA [B-cell maturation agent] and CD3. BCMA is highly expressed on myeloma cells and has limited expression on normal tissue, making it an ideal target for anti-myeloma strategies
Read More- https://www.delveinsight.com/asco-conference/article/teclistamab-asco?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
This document is a Form 16 certificate issued by DelveInsight Business Research LLP to Yashveer Bhardwaj for the assessment year 2022-23. It summarizes the salary paid, taxes deducted, and other income. The key details are:
- Gross salary paid was Rs. 3,71,540
- Standard deduction of Rs. 50,000 was claimed
- Total income chargeable was Rs. 3,21,540
- Total deductions under Chapter VI-A were Rs. 19,812
- Net tax payable was Rs. 0
The document is a Form 16 certificate issued by Delveinsight Business Research LLP to Yashveer Bhardwaj for the assessment year 2022-23. It summarizes that a total amount of Rs. 371540 was paid to Yashveer Bhardwaj from April 2021 to March 2022, but no tax was deducted at source by Delveinsight Business Research LLP. The certificate is signed by Vishal Agrawal on behalf of Delveinsight Business Research LLP.
Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%?
For More Information- https://www.delveinsight.com/asco-conference/article/roche-glofitamab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Genmab/Abbvie presented spectacular findings from arm 2 of the EPCORE NHL-2 (Phase Ib/II) trial in the patients with R/R Follicular Lymphoma.
Read More- https://www.delveinsight.com/asco-conference/article/genmab-abbvies-epcoritamab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Teclistamab is a bispecific antibody that targets BCMA [B-cell maturation agent] and CD3. BCMA is highly expressed on myeloma cells and has limited expression on normal tissue, making it an ideal target for anti-myeloma strategies
Read More- https://www.delveinsight.com/asco-conference/article/teclistamab-asco?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Hyperoxaluria is characterized by increased urinary excretion of oxalate. It can be caused by genetic mutations that result in oxalate overproduction (primary hyperoxaluria) or enteric hyperoxaluria, which can occur due to malabsorptive states and/or less well-understood genetic causes. Additionally, there are dietary factors that can impact urinary oxalate excretion. Primary and secondary hyperoxaluria are two distinct clinical expressions of hyperoxaluria.
For More Inquiry- https://www.delveinsight.com/infographics/primary-hyperoxaluria-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographic
Regional subgroup analysis of the Phase III TOPAZ-1 clinical trial of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). (Abstract # 4075)
Read More- https://www.delveinsight.com/asco-conference/article/durvalumab-immunotherapy?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
For More Information- https://www.delveinsight.com/infographics/chronic-obstructive-pulmonary-disease-copd-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographicc
Arcellx, Gracell Biotechnologies, and Oricell have demonstrated impressive clinical outcomes at ASCO 2022, posing a challenge to J&J/Legend Biotech’s and BMS's leading CAR-T cell therapies.
https://www.delveinsight.com/asco-conference/article/competitive-therapeutic-landscape-of-multiple-myeloma?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system.
https://www.delveinsight.com/infographics/multiple-sclerosis-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographic
Common Warts, also known as Verruca Vulgaris, is caused by non-malignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca Vulgaris.
CEL-SCI presented results from its Phase III IT-MATTERS study evaluating Multikine as a neoadjuvant therapy for advanced primary squamous cell carcinoma of the head and neck at ASCO 2022. The study showed a 14% absolute improvement in overall survival for lower-risk patients, representing the first positive randomized results in over 25 years for this population. Based on these results, CEL-SCI plans to file a BLA with the FDA for approval of Multikine for this indication.
A Quick Overview of Diffuse Large B-Cell Lymphoma (DLBCL) at ASCO 2022
To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed Coverage
Some of the Latest ASCO Abstract 2022 Launched: https://www.delveinsight.com/asco-conference/article/dlbcl-preview
Contact Us
Yash
info@delveinsight.com
The document summarizes three reports by DelveInsight on Vimpat API, Wet AMD Epidemiology, and Xarelto API. The Vimpat report provides details on the drug's manufacturer, mechanism of action, clinical trials, sales forecasts and patents. The Wet AMD report describes the disease, prevalence in the US expected to grow to 3 million cases by 2020, and risk factors like increasing with age. The Xarelto report similarly provides manufacturer details, mechanism, clinical trials, sales forecasts and competitive landscape. All reports use primary and secondary research from various sources.
Type 1 Diabetes,
Type 1 Diabetes market,
Type 1 Diabetes market report,
Type 1 Diabetes market research,
Type 1 Diabetes market share,
Type 1 Diabetes market size,
Type 1 Diabetes market trends,
Type 1 Diabetes market insights,
Type 1 Diabetes treatment market,
Type 1 Diabetes market drugs,
Hyperoxaluria is characterized by increased urinary excretion of oxalate. It can be caused by genetic mutations that result in oxalate overproduction (primary hyperoxaluria) or enteric hyperoxaluria, which can occur due to malabsorptive states and/or less well-understood genetic causes. Additionally, there are dietary factors that can impact urinary oxalate excretion. Primary and secondary hyperoxaluria are two distinct clinical expressions of hyperoxaluria.
For More Inquiry- https://www.delveinsight.com/infographics/primary-hyperoxaluria-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographic
Regional subgroup analysis of the Phase III TOPAZ-1 clinical trial of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). (Abstract # 4075)
Read More- https://www.delveinsight.com/asco-conference/article/durvalumab-immunotherapy?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
For More Information- https://www.delveinsight.com/infographics/chronic-obstructive-pulmonary-disease-copd-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographicc
Arcellx, Gracell Biotechnologies, and Oricell have demonstrated impressive clinical outcomes at ASCO 2022, posing a challenge to J&J/Legend Biotech’s and BMS's leading CAR-T cell therapies.
https://www.delveinsight.com/asco-conference/article/competitive-therapeutic-landscape-of-multiple-myeloma?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage
Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system.
https://www.delveinsight.com/infographics/multiple-sclerosis-market?utm_source=marketing&utm_medium=promotion&utm_campaign=infographic
Common Warts, also known as Verruca Vulgaris, is caused by non-malignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca Vulgaris.
CEL-SCI presented results from its Phase III IT-MATTERS study evaluating Multikine as a neoadjuvant therapy for advanced primary squamous cell carcinoma of the head and neck at ASCO 2022. The study showed a 14% absolute improvement in overall survival for lower-risk patients, representing the first positive randomized results in over 25 years for this population. Based on these results, CEL-SCI plans to file a BLA with the FDA for approval of Multikine for this indication.
A Quick Overview of Diffuse Large B-Cell Lymphoma (DLBCL) at ASCO 2022
To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed Coverage
Some of the Latest ASCO Abstract 2022 Launched: https://www.delveinsight.com/asco-conference/article/dlbcl-preview
Contact Us
Yash
info@delveinsight.com
The document summarizes three reports by DelveInsight on Vimpat API, Wet AMD Epidemiology, and Xarelto API. The Vimpat report provides details on the drug's manufacturer, mechanism of action, clinical trials, sales forecasts and patents. The Wet AMD report describes the disease, prevalence in the US expected to grow to 3 million cases by 2020, and risk factors like increasing with age. The Xarelto report similarly provides manufacturer details, mechanism, clinical trials, sales forecasts and competitive landscape. All reports use primary and secondary research from various sources.
Type 1 Diabetes,
Type 1 Diabetes market,
Type 1 Diabetes market report,
Type 1 Diabetes market research,
Type 1 Diabetes market share,
Type 1 Diabetes market size,
Type 1 Diabetes market trends,
Type 1 Diabetes market insights,
Type 1 Diabetes treatment market,
Type 1 Diabetes market drugs,
2. Vasomotor Symptoms (VMS) are episodes of profuse heat accompanied by sweating and
flushing, which are experienced majorly around the head, neck, chest, and upper back.
Vasomotor symptoms are often accompanied by hot flashes and night sweats and are often
considered as the cardinal symptoms of menopause. The VMS may also include heart palpitations
and changes in blood pressure.
Vasomotor Symptoms Epidemiology Segmentation in the 7MM
Total Prevalent Cases of Vasomotor Symptoms
Total Age-specific Cases of Vasomotor Symptoms
Total Treated Cases of Vasomotor Symptoms
Total Severity-specific Cases of Vasomotor Symptoms
Vasomotor Symptoms Epidemiological Insights Observed in the 7MM (2021)
The total prevalent cases of Vasomotor Symptoms in 7MM were estimated to be 136.02
million.
The Age-Specific prevalent cases of Vasomotor Symptoms in the 7MM were found to be 18.45
million in population aged between 40-44 years, 24.23 million in people with 45-49 years of
age, 26.15 million people of the age 50-54 years, 32.16 million of the population between 55-
59 years and 37.23 million people of the age 60-65 years.
Vasomotor Symptoms Market Insight
The market size of Vasomotor Symptoms in the 7MM was found to be approximately USD 15,026
million in the year 2021.
Vasomotor Symptoms Market Drivers
Increasing awareness
Rising emerging therapies
Novel mechanism of action
Increasing initiatives for R&D
Vasomotor Symptoms Market Barriers
Generic nature of the market
Limited understanding of the pathophysiology
Lack of robust developmental pipeline
Lack of trained and professional physicians
3. Vasomotor Symptoms Emerging Drugs
The emerging drugs in the Vasomotor Symptoms market are
Donesta (E4, Estetrol)
Elinzanetant (BAY-3427080, NT 814)
Fezolinetant (ESN-364)
MNGX-100 (Filgrastim, G-CSF)
Elismetrep (MT-8554)
Q-122 (MSX-122), and many others
Vasomotor Symptoms Key Players
The key players working in the Vasomotor Symptoms market are
Estetra
Mithra Pharmaceuticals
Bayer
Nerre Therapeutics Ltd.
Astellas Pharma
MenoGeniX
Mitsubishi Tanabe Pharma
QUE Oncology, and several others
Also, read- Vasomotor symptoms (Hot flashes/Night sweats) | Vasomotor symptoms (Hot
flashes/Night sweats) Infographics | Vasomotor symptoms (Hot flashes/Night sweats) Market